APRE Fundamental Analysis - APREA THERAPEUTICS INC

Name: APREA THERAPEUTICS INC (APRE) Stock
Brand: APREA THERAPEUTICS INC
Rating: 4 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to APRE. APRE was compared to 533 industry peers in the Biotechnology industry. APRE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. APRE is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year APRE has reported negative net income.

APRE had a negative operating cash flow in the past year.

In the past 5 years APRE always reported negative net income.

APRE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

APRE has a Return On Assets of -79.99%. This is in the lower half of the industry: APRE underperforms 67.54% of its industry peers.

APRE has a Return On Equity of -97.91%. This is comparable to the rest of the industry: APRE outperforms 46.72% of its industry peers.

		Industry Rank	Sector Rank
ROA	-79.99%
ROE	-97.91%
ROIC	N/A

ROA(3y)-163.39%

ROA(5y)-122.63%

ROE(3y)-186.11%

ROE(5y)-140.49%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

APRE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

APRE does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for APRE has been increased compared to 1 year ago.

Compared to 5 years ago, APRE has more shares outstanding

APRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

APRE has an Altman-Z score of -27.89. This is a bad value and indicates that APRE is not financially healthy and even has some risk of bankruptcy.

APRE's Altman-Z score of -27.89 is on the low side compared to the rest of the industry. APRE is outperformed by 87.99% of its industry peers.

There is no outstanding debt for APRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-27.89

ROIC/WACCN/A

WACC8.78%

2.3 Liquidity

A Current Ratio of 5.34 indicates that APRE has no problem at all paying its short term obligations.

The Current ratio of APRE (5.34) is comparable to the rest of the industry.

APRE has a Quick Ratio of 5.34. This indicates that APRE is financially healthy and has no problem in meeting its short term obligations.

APRE's Quick ratio of 5.34 is in line compared to the rest of the industry. APRE outperforms 59.29% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.34
Quick Ratio	5.34

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

APRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.35%, which is quite impressive.

The Revenue for APRE has decreased by -34.11% in the past year. This is quite bad

EPS 1Y (TTM)40.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.62%

Revenue 1Y (TTM)-34.11%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

APRE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.45% yearly.

Based on estimates for the next years, APRE will show a very strong growth in Revenue. The Revenue will grow by 144.32% on average per year.

EPS Next Y35.01%

EPS Next 2Y19.4%

EPS Next 3Y21.27%

EPS Next 5Y24.45%

Revenue Next Year-79.02%

Revenue Next 2Y-41.42%

Revenue Next 3Y180.65%

Revenue Next 5Y144.32%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

APRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APRE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as APRE's earnings are expected to grow with 21.27% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.4%

EPS Next 3Y21.27%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

APRE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

APREA THERAPEUTICS INC

NASDAQ:APRE (11/17/2025, 5:16:53 PM)

After market: 1.19 0 (0%)

1.19

-0.02 (-1.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-05 2025-11-05/bmo

Earnings (Next)03-23 2026-03-23/amc

Inst Owners24.64%

Inst Owner Change-10.82%

Ins Owners11.3%

Ins Owner Change0.68%

Market Cap6.94M

Revenue(TTM)841.00K

Net Income(TTM)-13.85M

Analysts85

Price Target10.71 (800%)

Short Float %1.04%

Short Ratio0.67

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)-4.35%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)246.91%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	8.25
P/FCF	N/A
P/OCF	N/A
P/B	0.49
P/tB	0.49
EV/EBITDA	N/A

EPS(TTM)-2.38

EYN/A

EPS(NY)-1.37

Fwd EYN/A

FCF(TTM)-2.18

FCFYN/A

OCF(TTM)-2.19

OCFYN/A

SpS0.14

BVpS2.43

TBVpS2.43

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-79.99%
ROE	-97.91%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-163.39%

ROA(5y)-122.63%

ROE(3y)-186.11%

ROE(5y)-140.49%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.34
Quick Ratio	5.34
Altman-Z	-27.89

F-Score3

WACC8.78%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)40.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.62%

EPS Next Y35.01%

EPS Next 2Y19.4%

EPS Next 3Y21.27%

EPS Next 5Y24.45%

Revenue 1Y (TTM)-34.11%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

Revenue Next Year-79.02%

Revenue Next 2Y-41.42%

Revenue Next 3Y180.65%

Revenue Next 5Y144.32%

EBIT growth 1Y-4.26%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-6.83%

EBIT Next 3Y-13.73%

EBIT Next 5Y-10.25%

FCF growth 1Y24.25%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y24.22%

OCF growth 3YN/A

OCF growth 5YN/A

APREA THERAPEUTICS INC / APRE FAQ

Can you provide the ChartMill fundamental rating for APREA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to APRE.

Can you provide the valuation status for APREA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to APREA THERAPEUTICS INC (APRE). This can be considered as Overvalued.

How profitable is APREA THERAPEUTICS INC (APRE) stock?

APREA THERAPEUTICS INC (APRE) has a profitability rating of 0 / 10.

What is the earnings growth outlook for APREA THERAPEUTICS INC?

The Earnings per Share (EPS) of APREA THERAPEUTICS INC (APRE) is expected to grow by 35.01% in the next year.

APREA THERAPEUTICS INC (APRE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

APREA THERAPEUTICS INC / APRE FAQ

Can you provide the ChartMill fundamental rating for APREA THERAPEUTICS INC?

Can you provide the valuation status for APREA THERAPEUTICS INC?

How profitable is APREA THERAPEUTICS INC (APRE) stock?

What is the earnings growth outlook for APREA THERAPEUTICS INC?